Why the study?
Although DOACs have similar or lower bleeding risk compared to warfarin, clinically relevant bleeding remains a risk, especially for patients with impaired organ function.
Key points are not available for this paper at this time.
Genetic fibrinogen SNPs may aid bleeding risk stratification in DOAC patients; leaves open validation across populations before clinical use.
Direct oral anticoagulants (DOACs) have become entrenched as the dominant anticoagulant over the last decade for patients with venous thrombosis and atrial fibrillation.1 Compared to warfarin, bleeding risk is similar or lower for patients on DOACs but clinically relevant bleeding is still a risk, especially for patients with impaired organ function.2
No takes yet. Share an insight, caveat, or question.
Hwang et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: